相关实验视频
Updated: Jun 29, 2025
06:21
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
106
结肠向pH响应的同性微滴剂用于治疗性结肠炎
Yinmei Tian1, Qian Hu1, Zhengjun Sun1
1Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, 430030, China.
Small (Weinheim an der Bergstrasse, Germany)
|April 5, 2024
概括
这项研究引入了一种用于治疗性结肠炎 (UC) 的新型协微滴系统. 该系统有效地将埃莫丁输送到结肠,减少炎症并改善肠道健康.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,影响生活质量,增加结肠直肠癌的风险.
- 在结肠病变中有效的口服药物输送和保留仍然是UC治疗的重大挑战.
- 由于易于制造和高药载荷,coacervate微滴具有药物输送的潜力.
研究的目的:
- 开发一种新的协微滴系统,用于性结肠炎中向口服药物输送.
- 评估开发系统的稳定性,结肠向能力和治疗疗效.
主要方法:
- 用Eudragit S100 (EU-Coac) 涂覆的生物相容的二甲基氨基乙烯-德克斯化/聚烯硫酸盐联合的制造.
- 将emodin装入EU-Coac (EMO@EU-Coac) 中,并评估其稳定性和pH响应的释放.
- 在体内评估EMO@EU-Coac在UC模型上的结肠向,保留和治疗效果.
主要成果:
- 开发的EU-Coac在胃条件和pH响应释放中表现出良好的稳定性.
- EMO@EU-Coac在口服后有效地向并保留在结肠中.
- 在UC模型中,用EMO@EU-Coac治疗减轻了炎症,氧化应激,修复了结肠表皮和平衡的肠道微生物群.
结论:
- 开发的EU-Coac系统为性结肠炎的向治疗提供了一种新且简单的方法.
- 这种共微滴传递系统显示出对管理UC的显著治疗潜力.
- 这项研究强调了共微滴在解决胃肠道疾病口服药物输送方面的挑战方面的承诺.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
01:21Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
179
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
179
01:26Peptic Ulcer Disease IV: Management
91
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91